Saturday July 22nd 2017

Brazil’s ANVISA approves Genzyme’s Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil’s national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

Read original article:  

Brazil’s ANVISA approves Genzyme’s Lemtrada for multiple sclerosis treatment

Leave a Comment

More from category

Mothers who breastfeed might have lower multiple sclerosis risk
Mothers who breastfeed might have lower multiple sclerosis risk

(Reuters Health) - Women who breastfeed may have a lower risk of developing multiple sclerosis later in life compared [Read More]

Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds
Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds

(Natural News) The results of a new pilot study showed the efficacy of lipoic acid in the reduction of whole brain [Read More]

Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs
Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs

MULTIPLE sclerosis - commonly abbreviated to MS - is a type of autoimmune disease which can cause problems with vision, [Read More]

National Patient-Advocacy Organizations Oppose ACA Repeal
National Patient-Advocacy Organizations Oppose ACA Repeal

/About-the-Society/News/National-Patient-Advocacy-Organizations-Oppose-ACA [Read More]

Exclusive: Nurses reluctant to discuss disability with MS patients
Exclusive: Nurses reluctant to discuss disability with MS patients

Nearly two-thirds of specialist nurses are reluctant to discuss disability with patients who have multiple sclerosis, [Read More]